Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel agents for chemoprevention, screening methods, and sampling issues.

Mary Jo Fackler1, Ella Evron, Seema A Khan

  • 1Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231-1000, USA.

Journal of Mammary Gland Biology and Neoplasia
|November 1, 2003
PubMed
Summary

Preventing breast cancer requires novel chemopreventive agents and improved risk assessment methods. This review covers promising agents and new biomarkers for future clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of the cf-MMSP assay for enhanced analytical sensitivity of methylated DNA in breast cancer liquid biopsy.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Simvastatin Treatment in Patients with Liver Cirrhosis: a Phase II Randomized Placebo Controlled Trial Shows Reduction in IL-6 Levels.

Cancer prevention research (Philadelphia, Pa.)·2026
Same author

Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet).

Frontiers in immunology·2026
Same author

CRYβB2 is a biomarker for poor prognosis and response to CDK4/6 inhibitors in breast cancer.

Breast cancer research : BCR·2026
Same author

Reprogramming SREBP1-dependent lipogenesis and inflammation in high-risk breast with licochalcone A: A novel path to cancer prevention.

International journal of cancer·2025
Same author

Medium-Chain Fatty Acid exposure in non-transformed mammary glands leads to pro-tumorigenic alterations associated with aging.

bioRxiv : the preprint server for biology·2025

Area of Science:

  • Oncology
  • Preventive Medicine
  • Biomarker Research

Background:

  • Effective breast cancer control necessitates a dual approach of prevention and treatment.
  • Current clinical trials for chemopreventive agents have yielded limited success.
  • Numerous novel breast cancer chemopreventive agents are under development for clinical trials.

Purpose of the Study:

  • To review novel breast cancer chemopreventive agents and approaches.
  • To discuss advancements in risk assessment, sampling, and biomarker development.
  • To explore factors influencing the selection of chemopreventive agents and clinical trial design.

Main Methods:

  • Review of existing literature on breast cancer chemoprevention.
  • Identification of agents currently in clinical trials or preclinical development.

Related Experiment Videos

  • Analysis of novel methods for risk assessment and biomarker identification.

    • Main Results:

    • A range of new chemopreventive agents are progressing towards clinical trials.
    • Novel imaging techniques and breast sampling methods show promise for risk assessment.
    • Development of intermediate biomarkers is crucial for future progress.

    Conclusions:

    • Advancing breast cancer prevention requires both new chemopreventive agents and innovative trial methodologies.
    • Improved risk stratification and surrogate endpoints are essential for successful clinical trials.
    • A comprehensive strategy integrating novel agents, biomarkers, and trial designs is needed for effective breast cancer control.